Baxter International is set to drop its earnings report this Thursday, having just smashed revenue and EPS targets last quarter with $2.7 billion in sales—up nearly 3% year-over-year—and even beating its own full-year guidance. Analysts expect a more modest, flat revenue performance this quarter, down from last year’s 4% growth, with no major surprises anticipated. While competitors like Abbott and Intuitive Surgical posted stronger gains, Baxter’s recent misses have raised questions. Still, the healthcare equipment sector is on fire, up 4.4% this month, and Baxter’s shares have surged 11.3%—now trading around $24.50, with a target price near $23. Will Baxter sustain its momentum—or will the slowdown be the headline?
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
